Characterization of a Long-Acting Site-Specific PEGylated Murine GM-CSF Analog and Analysis of Its Hematopoietic Properties in Normal and Cyclophosphamide-Treated Neutropenic Rats
- PMID: 32172395
- DOI: 10.1007/s10930-020-09894-0
Characterization of a Long-Acting Site-Specific PEGylated Murine GM-CSF Analog and Analysis of Its Hematopoietic Properties in Normal and Cyclophosphamide-Treated Neutropenic Rats
Abstract
Previously we reported that site-specific modification of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) A3C analog with polyethylene glycol (PEG) dramatically improved the pharmacokinetic properties of the protein in rats. However, we could not evaluate the hematological properties of the PEG-A3C protein in rats because human GM-CSF is inactive in rodents. To study the biological effects of PEGylated GM-CSF analogs in rodents we created a homologous site-specific PEGylated murine (mu) GM-CSF (T3C) protein. muGM-CSF and the T3C protein were expressed in Escherichia coli and purified by column chromatography. The purified T3C protein was covalently modified with a linear 20 kDa- or a branched 40 kDa-maleimide-PEG, and the monoPEGylated proteins purified by column chromatography. muGM-CSF, T3C and the two PEG-T3C proteins had comparable in vitro biological activities, as measured by stimulation of proliferation of the murine FDC-P1 cell line. The PEG-T3C proteins had 10- to 25-fold longer circulating half-lives than muGM-CSF and stimulated greater and longer lasting increases in neutrophils and white blood cells than muGM-CSF following a single intravenous or subcutaneous administration to rats. Treatment of rats made neutropenic with cyclophosphamide with the PEG-T3C proteins shortened the time for recovery of neutrophils to normal levels from 9 or 10 days to 5 or 6 days, whereas muGM-CSF showed no benefit versus vehicle solution. Acceleration of neutrophil recovery in cyclophosphamide-treated rats required a minimum of three PEG-T3C treatments over five days. The PEG-T3C proteins should prove useful for evaluating the potential therapeutic benefits of GM-CSF and long-acting GM-CSF proteins in rodent disease models.
Keywords: Cysteine mutein; Expression; Granulocyte macrophage colony-stimulating factor; Hematopoiesis; Neutropenia; Polyethylene glycol.
Similar articles
-
Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor.Bioconjug Chem. 2005 Sep-Oct;16(5):1291-8. doi: 10.1021/bc050172r. Bioconjug Chem. 2005. PMID: 16173810 Free PMC article.
-
Hematopoietic properties of granulocyte colony-stimulating factor/immunoglobulin (G-CSF/IgG-Fc) fusion proteins in normal and neutropenic rodents.PLoS One. 2014 Mar 17;9(3):e91990. doi: 10.1371/journal.pone.0091990. eCollection 2014. PLoS One. 2014. PMID: 24637521 Free PMC article.
-
Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study.Clin Pharmacol Drug Dev. 2021 Mar;10(3):291-298. doi: 10.1002/cpdd.819. Epub 2020 Jun 21. Clin Pharmacol Drug Dev. 2021. PMID: 32567217 Clinical Trial.
-
PEGylated G-CSF (BBT-015), GM-CSF (BBT-007), and IL-11 (BBT-059) analogs enhance survival and hematopoietic cell recovery in a mouse model of the hematopoietic syndrome of the acute radiation syndrome.Health Phys. 2014 Jan;106(1):7-20. doi: 10.1097/HP.0b013e3182a4dd4e. Health Phys. 2014. PMID: 24276546 Free PMC article.
-
PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies.Drug Metab Dispos. 2007 Jan;35(1):9-16. doi: 10.1124/dmd.106.012419. Epub 2006 Oct 4. Drug Metab Dispos. 2007. PMID: 17020954 Review.
Cited by
-
Polypharmacy to Mitigate Acute and Delayed Radiation Syndromes.Front Pharmacol. 2021 May 17;12:634477. doi: 10.3389/fphar.2021.634477. eCollection 2021. Front Pharmacol. 2021. PMID: 34079456 Free PMC article.
-
Construction of Recombinant Human GM-CSF and GM-CSF-ApoA-I Fusion Protein and Evaluation of Their Biological Activity.Pharmaceuticals (Basel). 2021 May 13;14(5):459. doi: 10.3390/ph14050459. Pharmaceuticals (Basel). 2021. PMID: 34068113 Free PMC article.
-
The delayed effects of acute radiation exposure (DEARE): characteristics, mechanisms, animal models, and promising medical countermeasures.Int J Radiat Biol. 2023;99(7):1066-1079. doi: 10.1080/09553002.2023.2187479. Epub 2023 Mar 16. Int J Radiat Biol. 2023. PMID: 36862990 Free PMC article. Review.
-
Danggui Jixueteng decoction for the treatment of myelosuppression after chemotherapy: A combined metabolomics and network pharmacology analysis.Heliyon. 2024 Jan 19;10(3):e24695. doi: 10.1016/j.heliyon.2024.e24695. eCollection 2024 Feb 15. Heliyon. 2024. PMID: 38314262 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials